Prognostic significance of baseline reverse transcriptase-PCR for prostate-specific antigen in men with hormone-refractory prostate cancer treated with chemotherapy Journal Article

  

Authors:	Ross, R. W.; Manola, J.; Hennessy, K.; Galsky, M.; Scher, H.; Small, E.; Kelly, W. K.; Kantoff, P. W.
Article Title:	Prognostic significance of baseline reverse transcriptase-PCR for prostate-specific antigen in men with hormone-refractory prostate cancer treated with chemotherapy
Abstract:	Purpose: Methods accurately categorizing the diverse biology of prostate cancer are needed. A positive baseline reverse transcriptase-PCR for prostate-specific antigen (RT-PCR PSA) in the androgen-independent setting is an independent prognostic marker of survival. The objectives of the current study were to examine the prognostic implication of baseline RT-PCR PSA positivity during treatment with an active chemotherapeutic agent and explore whether an RT-PCR PSA "response" provides prognostic information. Materials and Methods: In a combined analysis of a phase I and a randomized phase II trial of BMS-247550 (an epothilone B analogue), 104 patients with hormone-refractory prostate cancer had whole blood samples collected at baseline, then with each cycle of therapy. RT-PCR PSA was assessed and related to time to progression (TTP). Results: From 100 evaluable patients, 368 samples were received, of which 90.8% were evaluable for RT-PCR PSA status. Baseline RT-PCR PSA status was significantly associated with TTP (hazard ratio, 2.22; 95% confidence interval, 1.40-3.52). Twenty-six of 38 patients positive at first assessment had at least one follow-up RT-PCR PSA that was negative ("response"). In univariate analysis, RT-PCR PSA response was not significantly associated with TTP, but in multivariate analysis, RT-PCR PSA response was of borderline statistical significance in predicting TTP (hazard ratio, 0.41; 95% confidence interval, 0.16-1.01). Conclusion: These results provide further confirmation that baseline RT-PCR PSA is a statistically significant predictor of TTP in hormone-refractory prostate cancer. Moreover, this is the first report to suggest that RT-PCR PSA response during chemotherapy treatment may predict TTP. © 2005 American Association for Cancer Research.
Keywords:	adult; cancer chemotherapy; cancer survival; treatment outcome; aged; aged, 80 and over; middle aged; major clinical study; clinical trial; follow-up studies; prostate specific antigen; reverse transcription polymerase chain reaction; tumor markers, biological; drug resistance, neoplasm; prostate cancer; prostate-specific antigen; prostatic neoplasms; reverse transcriptase polymerase chain reaction; disease progression; reference values; predictive value of tests; phase 1 clinical trial; antineoplastic agents, hormonal; ixabepilone; estramustine
Journal Title:	Clinical Cancer Research
Volume:	11
Issue:	14
ISSN:	1078-0432
Publisher:	American Association for Cancer Research
Date Published:	2005-07-15
Start Page:	5195
End Page:	5198
Language:	English
DOI:	10.1158/1078-0432.ccr-05-0431
PUBMED:	16033836
PROVIDER:	scopus
DOI/URL:	http://www.scopus.com/inward/record.url?eid=2-s2.0-22344453816&partnerID=40&md5=65a6f2b5caf3239e5f33219e4d16936f
Notes:	--- - "Cited By (since 1996): 11" - "Export Date: 24 October 2012" - "CODEN: CCREF" - "Source: Scopus"

https://synapse.mskcc.org/synapse/works/has_related_data_chk/35763